CN105659095B - 在心力衰竭中用于抑制素治疗分层的标记物 - Google Patents

在心力衰竭中用于抑制素治疗分层的标记物 Download PDF

Info

Publication number
CN105659095B
CN105659095B CN201480058798.3A CN201480058798A CN105659095B CN 105659095 B CN105659095 B CN 105659095B CN 201480058798 A CN201480058798 A CN 201480058798A CN 105659095 B CN105659095 B CN 105659095B
Authority
CN
China
Prior art keywords
patient
biomarker
level
sample
statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480058798.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105659095A (zh
Inventor
D.布洛克
H.布伦纳
T.迪特勒
U-H.温许斯-特伦
C.曹格
A.齐格勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201911022375.7A priority Critical patent/CN110658344A/zh
Publication of CN105659095A publication Critical patent/CN105659095A/zh
Application granted granted Critical
Publication of CN105659095B publication Critical patent/CN105659095B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/62—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving urea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480058798.3A 2013-08-26 2014-08-26 在心力衰竭中用于抑制素治疗分层的标记物 Expired - Fee Related CN105659095B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911022375.7A CN110658344A (zh) 2013-08-26 2014-08-26 在心力衰竭中用于抑制素治疗分层的标记物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13181687.8A EP2843414B1 (en) 2013-08-26 2013-08-26 Marker for statin treatment stratification in heart failure
EP13181687.8 2013-08-26
PCT/EP2014/068090 WO2015028469A2 (en) 2013-08-26 2014-08-26 Marker for statin treatment stratification in heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911022375.7A Division CN110658344A (zh) 2013-08-26 2014-08-26 在心力衰竭中用于抑制素治疗分层的标记物

Publications (2)

Publication Number Publication Date
CN105659095A CN105659095A (zh) 2016-06-08
CN105659095B true CN105659095B (zh) 2019-11-05

Family

ID=49029008

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480058798.3A Expired - Fee Related CN105659095B (zh) 2013-08-26 2014-08-26 在心力衰竭中用于抑制素治疗分层的标记物
CN201911022375.7A Pending CN110658344A (zh) 2013-08-26 2014-08-26 在心力衰竭中用于抑制素治疗分层的标记物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201911022375.7A Pending CN110658344A (zh) 2013-08-26 2014-08-26 在心力衰竭中用于抑制素治疗分层的标记物

Country Status (6)

Country Link
US (3) US10234464B2 (enExample)
EP (2) EP2843414B1 (enExample)
JP (3) JP6625535B2 (enExample)
CN (2) CN105659095B (enExample)
CA (1) CA2920066A1 (enExample)
WO (1) WO2015028469A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
CN106018789A (zh) * 2016-08-03 2016-10-12 北京德奥平生物技术有限公司 一种st2定量检测方法及试剂盒
WO2018167447A1 (en) 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
US11942219B1 (en) * 2017-09-25 2024-03-26 Cerner Innovation, Inc. Determining a cardiovascular ischemic event and decision support tool
EP3899035B1 (en) * 2018-12-20 2025-04-16 F. Hoffmann-La Roche AG Detection of target nucleic acid by solid-phase molography
CN110361544A (zh) * 2019-07-29 2019-10-22 清华大学深圳研究生院 P1np检测试纸、p1np检测试剂盒和检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101517415A (zh) * 2006-08-04 2009-08-26 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
WO2009138451A1 (en) * 2008-05-15 2009-11-19 F. Hoffmann La-Roche Ag Multimarker panel for the differentiation of dilated cardiomyopathy and as basis for a differential therapy and its result

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5695761A (en) 1993-12-23 1997-12-09 Rutgers University Suppression of nitric oxide production by osteopontin
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
US6414219B1 (en) 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
ATE348164T1 (de) 1999-05-17 2007-01-15 Bioph Biotech Entw Pharm Gmbh Neuroprotektive eigenschaften von gdf-15, ein mitglied der tgf-beta superfamilie
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
DE50309809D1 (de) 2002-11-16 2008-06-19 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
DE102004051847B4 (de) * 2004-10-25 2008-09-18 Dade Behring Marburg Gmbh Verhältnis von PIGF und Flt-1 als prognostischer Parameter bei kardio-vaskulären Erkrankungen
EP1929295A4 (en) * 2005-08-30 2010-03-17 Biosite Inc USE OF SOLUBLE FLT-1 AND ITS FRAGMENTS IN CARDIOVASCULAR CONDITIONS
WO2007026214A1 (en) 2005-08-31 2007-03-08 Inverness Medical Switzerland Gmbh Predicting responses to drugs or drug candidates
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
WO2008015254A2 (en) 2006-08-04 2008-02-07 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
EP2498095A3 (en) * 2007-01-25 2012-11-28 Roche Diagniostics GmbH Use of IGFBP-7 in the assessment of heart failure
US20100267062A1 (en) * 2007-09-26 2010-10-21 Norbert Frey Osteopontin as Novel Prognostic Biomarker for Heart Failure
JP2011501112A (ja) * 2007-10-10 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー 心筋梗塞のモニタリング及びその治療のための手段及び方法
CA2703979A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic ether and thioether derivatives and methods of use thereof
CA2710035C (en) * 2007-12-21 2018-01-16 Mcmaster University Method for assessing risk of heart failure
CA2711221C (en) * 2007-12-31 2017-02-28 Emory University Triarylmethane analogs and their use in treating cancers
WO2009137006A2 (en) * 2008-04-30 2009-11-12 The University Of North Carolina At Chapel Hill Directed evolution and in vivo panning of virus vectors
WO2009144307A1 (en) * 2008-05-29 2009-12-03 F. Hoffmann-La Roche Ag MEANS AND METHODS FOR IDENTIFYING A SUBJECT BEING SUSCEPTIBLE TO A CARDIAC THERAPY BASED ON DETERMINATION OF A CARDIAC TROPONIN, sCD40L AND C-REACTIVE PROTEIN
CN106370857A (zh) * 2008-10-21 2017-02-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
BRPI0920069A8 (pt) 2008-10-30 2017-10-03 Centre De Rech Public De La Sante Biomarcadores
US20120157378A1 (en) * 2008-11-14 2012-06-21 Simin Liu Methods and Compositions for Predicting a Subject's Susceptibility To and Risk of Developing Type 2 Diabetes
EP2425245B1 (en) * 2009-04-27 2016-10-05 Roche Diagnostics GmbH Use of endostatin as a marker of heart failure
WO2011064358A1 (en) * 2009-11-27 2011-06-03 Roche Diagnostics Gmbh Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction
KR20130040844A (ko) * 2010-03-29 2013-04-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 약학적으로 유발된 전이유전자 제거 시스템
WO2012003475A1 (en) * 2010-07-02 2012-01-05 Bg Medicine, Inc. Statin therapy monitored by galectin- 3 measurement
EP2367006A1 (en) * 2010-08-24 2011-09-21 Roche Diagnostics GmbH PLGF-based means and methods for diagnosing cardiac causes in acute inflammation
WO2012028713A1 (en) * 2010-09-02 2012-03-08 Roche Diagnostics Gmbh Method for diagnosing and monitoring the cardiac pathophysiological state in a subject undergoing or having undergone percutaneous coronary intervention (pci)
US20120219943A1 (en) * 2011-02-03 2012-08-30 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101517415A (zh) * 2006-08-04 2009-08-26 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
WO2009138451A1 (en) * 2008-05-15 2009-11-19 F. Hoffmann La-Roche Ag Multimarker panel for the differentiation of dilated cardiomyopathy and as basis for a differential therapy and its result

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biomarkers and diagnostics in heart failure;Hanna K.et al.;《Biochimica et Biophysica Acta》;20130109;全文 *
Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure;Tibor Kempf, MD, et al.;《Journal of the American College of Cardiology》;20070911;全文 *

Also Published As

Publication number Publication date
JP2016529505A (ja) 2016-09-23
HK1225443A1 (zh) 2017-09-08
JP2021185371A (ja) 2021-12-09
EP3441768A2 (en) 2019-02-13
US20190154706A1 (en) 2019-05-23
US11460474B2 (en) 2022-10-04
CA2920066A1 (en) 2015-03-05
US20220206015A1 (en) 2022-06-30
US20160169911A1 (en) 2016-06-16
CN105659095A (zh) 2016-06-08
EP3441768A3 (en) 2019-03-20
CN110658344A (zh) 2020-01-07
JP6625535B2 (ja) 2019-12-25
EP2843414B1 (en) 2018-09-19
US10234464B2 (en) 2019-03-19
WO2015028469A2 (en) 2015-03-05
JP6934508B2 (ja) 2021-09-15
JP2020046432A (ja) 2020-03-26
WO2015028469A3 (en) 2015-05-07
EP2843414A1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
JP6977081B2 (ja) ナトリウム利尿ペプチドによってガイドされる、心不全患者におけるリスク評価および治療監視のためのバイオマーカー
US20220206015A1 (en) Marker for statin treatment stratification in heart failure
JP6756772B2 (ja) 心不全の治療選択におけるバイオマーカー
CN106461672B (zh) 用于诊断舒张功能障碍的igfbp7
CN105960593B (zh) 用于慢性肾病进展预测的生物标记物和方法
HK40012676A (en) Marker for statin treatment stratification in heart failure
HK1225443B (zh) 在心力衰竭中用於抑制素治疗分层的标记物
HK40012159A (en) Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
HK1228997B (zh) 用於在由利钠肽指导的心力衰竭患者中风险评估和治疗监测的生物标记物
HK1228997A1 (en) Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides
HK1234493B (zh) 用於诊断舒张功能障碍的igfbp7
CN117242349A (zh) 用于脓毒症的早期检测的igfbp7标志物组
HK1213324B (zh) 心力衰竭疗法的选择中的生物标记物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1225443

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191105